Here is a synopsis of all four stocks:

Bull of the Day:

Our Bull of the Day recommendation is for CV Therapeutics (Nasdaq:CVTX). Headquartered in Palo Alto, CA, CVTX is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. Ranexa has been approved and CVT kicked-off the ramp at ACC in March 2006. Longer term, the MERLIN study will determine the ultimate success of the drug. Aceon is finally contributing and phase III regadenoson looks promising. We see the stock fairly valued at $30, and thus rate the shares a Buy.

Bear of the Day:

Our Bear of the Day is for Altria Group, Inc. (NYSE:MO), the leading domestic tobacco company. The company generates significant cash flow and has a high dividend yield. However, the company is engaged in numerous tobacco liability suits. Of immediate concern is the trend of excessive punitive damage awards being upheld by appellate courts, especially the $50 million judgment paid out in the Boeken case after the U.S. Supreme Court refused to hear it. This decision will entice lawyers to file more cases against the tobacco companies. Also, potential negative litigation is expected in Canada. Finally, weak volumes in Germany and a price war in Spain remain concerns. The stock is rated a Sell.

Analyst Blog:

We are maintaining our Hold recommendation on British Airways (NYSE:BAB) prior to its fourth quarter and year-end results, which are due on May 19. We think that oil prices will come down in the future, and this should translate to higher profits for BAB, given that jet fuel costs are one of the most important profit drivers for an airline. However, at its current valuation, the stock is fairly valued in our view.

Honda Motor Company (NYSE:HMC) is expanding its business in Asia, growing its global network to increase efficiency and introducing new products to satisfy local markets. Further, capacity expansion plans in Asia, a new sales strategy in Japan, and a proposed launch of Accura in Japan make us optimistic about Honda's future prospects. Therefore, we rate it a Buy with a six-month target price of $37.00.

Get the full analysis of all four stocks by going to http://at.zacks.com/?id=2649.

About the Bull and Bear of the Day

Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.

About the Analyst Blog

Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2677.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros by going to http://at.zacks.com/?id=2650.

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

(a) The Zacks Performance Rank performance is the total return of equal weighted simulated portfolios consisting of those stocks with the indicated Zacks Rank net of fees. Results reflect the reinvestment of dividends and other earnings. Simulated results do not represent actual trading and may not reflect the impact that economic and market factors might have had on decision-making if an adviser were actually managing a client's money.

(b) The S&P 500 Index ("S&P 500") is a well-known, unmanaged index of the prices of 500 large-company common stocks selected by Standard & Poor's. The S&P 500 includes the reinvestment of all dividends, no transaction costs, and represents the gross returns before management fees.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.